TTrialPathMatch Me to Trials
← Back to trials
RecruitingHematological Malignancies

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Eligible age

18+ yrs

Accepts

All genders

Locations

12 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).

Sponsor: Janssen Research & Development, LLC

You may qualify if…

  • ✓ Documented initial diagnosis of multiple myeloma according to international myeloma working group (IMWG) diagnostic criteria
  • ✓ Part 3: Measurable disease cohort A, cohort B, cohort C and cohort D: multiple myeloma must be measurable by central laboratory assessment; Cohort E: Multiple myeloma must be measurable by local laboratory assessment
  • ✓ Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
  • ✓ Women of childbearing potential must have a negative pregnancy test at screening and prior to the first dose of study drug using a highly sensitive pregnancy test either serum (beta human chorionic gonadotropin \[hCG\]) or urine
  • ✓ Willing and able to adhere to the prohibitions and restrictions specified in this protocol

You may not qualify if…

  • ✕ Part 3 only: Cohort A and Cohort C only: exposed to a CAR-T or T cell redirection therapy at any time. Cohort B, Cohort D and Cohort E: T cell redirection therapy within 3 months
  • ✕ Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy
  • ✕ Received a cumulative dose of corticosteroids equivalent to \>= 140 milligram (mg) of prednisone within the 14-day period before the first dose of study drug (does not include pretreatment medication)
  • ✕ Stroke or seizure within 6 months prior to signing the informed consent form (ICF)

Where it's recruiting

Alabama

Birmingham

Arkansas

Little Rock

Florida

Hollywood

Georgia

Atlanta

Illinois

Chicago

Kentucky

Louisville

Michigan

Ann Arbor

Missouri

St Louis

New York

New York · Rochester

Oregon

Portland

Tennessee

Nashville

Source: ClinicalTrials.gov · NCT04634552 · last updated 2026-11-03

A Study of Talquetamab in Participants With Relapsed or Refractory Mul · TrialPath